Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Other Operating Expenses (2020 - 2025)

Maxcyte (MXCT) has disclosed Other Operating Expenses for 6 consecutive years, with -$9.6 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 21.8% to -$9.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$45.3 million through Dec 2025, up 5.5% year-over-year, with the annual reading at -$46.5 million for FY2025, 2.61% up from the prior year.
  • Other Operating Expenses for Q4 2025 was -$9.6 million at Maxcyte, up from -$12.4 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $8.3 million in Q4 2023, with the low at -$13.2 million in Q3 2024.
  • Average Other Operating Expenses over 5 years is -$1.3 million, with a median of $3.4 million recorded in 2021.
  • The sharpest move saw Other Operating Expenses skyrocketed 75.49% in 2021, then crashed 263.61% in 2024.
  • Over 5 years, Other Operating Expenses stood at $4.5 million in 2021, then skyrocketed by 39.81% to $6.3 million in 2022, then surged by 32.15% to $8.3 million in 2023, then plummeted by 248.56% to -$12.3 million in 2024, then increased by 21.8% to -$9.6 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at -$9.6 million, -$12.4 million, and -$12.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.